Pharmaceutical care for a case of voriconazole combined with micafungin in the treatment of chronic obstructive pulmonary disease patients with pulmonary aspergillus infection

doi:10.19803/j.1672-8629.20210808

Abstract

Abstract: Objective To analyze the process of treatment and priorities of pharmaceutical care during the treatment of chronic obstructive pulmonary disease (COPD) complicated with invasive aspergillosis with voriconazole combined with micafungin. Methods Clinical pharmacists participated in the treatment and monitoring of a patient, selected drugs according to the metabolic kinetic characteristics of different drugs in the body, and provided pharmaceutical care during the treatment based on the condition of the patient. Results Upon participation in the treatment, the pharmacists recommended voriconazole combined with micafungin to alleviate the condition and prevent serious adverse drug reactions. Conclusion Selection of the right antibiotics is crucial to the efficacy of treatment of COPD with invasive aspergillosis. Clinical pharmacists should actively participate in pharmaceutical care of patients in critical condition.

Key words: voriconazole, micafungin, invasive pulmonary aspergillosis, chronic obstructive pulmonary disease, pharmaceutical care

CLC Number:

R994.1

ZHANG Li, CHEN Haitao, CHEN Xueliang, GAO Xiurong. Pharmaceutical care for a case of voriconazole combined with micafungin in the treatment of chronic obstructive pulmonary disease patients with pulmonary aspergillus infection[J]. Chinese Journal of Pharmacovigilance, 2022, 19(12): 1380-1383.

References

[1] CHEN LX, CHEN DC.Update and analysis of clinical diagnosis and treatment guidelines for aspergillus infection (IDSA 2016 Edition)[J].Chinese Journal of Medicine(中国医刊), 2018,53(6): 595-598.
[2] Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease[R/OL].[2021-02-20].https://goldcopd.org.
[3] BADDLEY JW.Clinical risk factors for invasive aspergillosis[J]. Medical Mycology, 2011, 49(Suppl 1): S7-S12.
[4] BAO ZJ, XU JP, CHEN AF.Risk factors for secondary pulmonary fungal infection in patients with chronic obstructive pulmonary disease[J].Chinese Journal of Nosocomiology(中华医院感染学杂志), 2014, 24(17):4245-4247.
[5] WANG C, CHI CH, CHEN RC, et al.Guideline for primary care of chronic obstructive pulmonary disease (2018)[J]. Chinese Journal of General Practitioners(中华全科医师杂志), 2018, 17(11): 856-870.
[6] Working Group on Revision of Guiding Principles for Clinical Application of Antibiotics. Guiding Principles of Clinical Use of Antibiotics(2015)(抗菌药物临床应用指导原则2015年版)[M]. Beijing People’s Medical Publishing House, 2015.
[7] Infection Group of Chinese Thoracic Society.Chinese Journal of Tuberculosis and Respiratory Editorial Committee.Expert consensus on diagnosis and treatment of pulmonary mycosis[J].Chinese Journal of Tuberculosis and Respiratory Diseases(中华结核和呼吸杂志), 2007, 30(11):821-834.
[8] PATTERSON TF, THOMPSON GR 3RD, DENNING DW, et a1. Practice guidelines for the diagnosis and management of aspergillosis:2016 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2016, 63(4): el-e60.
[9] ZONIOS D, YAMAZAKI H,MURAYAMA N, et al.Voriconazole metabolism,toxicity,and the effect of cytochrome P450 2C19 genotype[J]. J Infect Dis, 2014, 209: 1941-1948.
[10] ZHANG XJ, CAI R, LAI B, et al.Study on the risk factors of voriconazole hepatotoxicity[J]. Hebei Medical Journal(河北医药), 2016, 38(4): 617-620.
[11] CHEN K, ZHANG X, KE X, et al.Individalized medication of voriconazole:a practice guideline of the division of therapeutic drug monitoring, Chinese pharmacological society[J]. Ther Drug Monit, 2018, 40(6): 663-674.
[12] Chinese Medical Association, Chinese Medical Association Publishing House, Chinese Society of Gastroenterology, et al. Guideline for primary care of drug-induced liver injury(2019)[J]. Chinese Journal of General Practitioners(中华全科医师杂志), 2020, 19(10):868-875.
[13] ZHOU R, CHEN ZZ.Pharmacists’participation in the treatment of a patient with complicated abdominal infection secondary to invasive fungal infection[J].Chinese Journal of Pharmacovigilance(中国药物警戒), 2020,17(2): 106-110.
[14] CHEN DC, FENG SZ, HU JD, et al.Multidisciplinary clinical evaluation of micafungin[J].The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2014, 30(11): 1071-1078.
[15] CORNELY OA, SIDHU M, ODEYEMI I, et al.Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany[J]. Curr Med Res Opin, 2008, 24: 1743-1753.
[16] NEOH CF, LIEW D, SLAVIN MA, et al.Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis[J]. Intern Med J, 2013, 43: 668-677.
[17] SHU YQ, LI Y.Clinical effectiveness and utilization review of caspofungin and micafungin in treatment of in-vasive fungal infections in critical patients[J]. Practical Journal of Clinical Medicine(实用医院临床杂志), 2012, 9(5): 80-82.
[18] WANG FL, JIANG T, ZHENG LL.Pulmonary coinfection by aspergillus and pneumocystis jirovecii:a case report and Literature review[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2021, 41(13): 1372-1376.
[19] WANG L, GAO LJ, AN Y, et al.Diagnostic value of serum aspergillus-specific IgG and IgE in allergic bronchopulmonary aspergillosis[J].Guangxi Medical Journal(广西医学), 2020, 42(23): 3039-3042.
[20] ZHANG Y, MIU Q, JIN WT, et al.Etiological dignostic value of metagenomic next-generation sequencing in chronic pulmonary aspergillosis[J]. Chinese Journal of Clinical Medicine(中国临床医学), 2020, 27(4): 563-566.